Your browser doesn't support javascript.
loading
Virological characteristics of the SARS-CoV-2 BA.2.86 variant.
Tamura, Tomokazu; Mizuma, Keita; Nasser, Hesham; Deguchi, Sayaka; Padilla-Blanco, Miguel; Oda, Yoshitaka; Uriu, Keiya; Tolentino, Jarel E M; Tsujino, Shuhei; Suzuki, Rigel; Kojima, Isshu; Nao, Naganori; Shimizu, Ryo; Wang, Lei; Tsuda, Masumi; Jonathan, Michael; Kosugi, Yusuke; Guo, Ziyi; Hinay, Alfredo A; Putri, Olivia; Kim, Yoonjin; Tanaka, Yuri L; Asakura, Hiroyuki; Nagashima, Mami; Sadamasu, Kenji; Yoshimura, Kazuhisa; Saito, Akatsuki; Ito, Jumpei; Irie, Takashi; Tanaka, Shinya; Zahradnik, Jiri; Ikeda, Terumasa; Takayama, Kazuo; Matsuno, Keita; Fukuhara, Takasuke; Sato, Kei.
Afiliação
  • Tamura T; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan; One Health Research Center, Hokkaido University, Sapporo, Japan; Graduate School of Medicine, Hokkaido Uni
  • Mizuma K; Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Nasser H; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan; Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
  • Deguchi S; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
  • Padilla-Blanco M; First Medical Faculty at Biocev, Charles University, Vestec-Prague, Czechia; Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain.
  • Oda Y; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Uriu K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Tolentino JEM; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan.
  • Tsujino S; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Suzuki R; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan.
  • Kojima I; Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Nao N; Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan; One Health Research Center, Hokkaido University, Sapporo, Japan; Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Shimizu R; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
  • Wang L; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan.
  • Tsuda M; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan.
  • Jonathan M; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
  • Kosugi Y; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Guo Z; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Hinay AA; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Putri O; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Indonesia International Institute for Life Sciences (i3L), Jakarta, Indonesia.
  • Kim Y; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Faculty of Natural Science, Imperial College London, London, UK.
  • Tanaka YL; Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan.
  • Asakura H; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Nagashima M; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Sadamasu K; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Yoshimura K; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Saito A; Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan; Center for Animal Disease Control, University of Miyazaki, Miyazaki, Japan; Graduate School of Medicine and Veterinary Medicine, University of Miyazaki, Miyazaki, Japan.
  • Ito J; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Irie T; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Tanaka S; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan. Electronic address: tanaka@med.hokudai.ac.jp.
  • Zahradnik J; First Medical Faculty at Biocev, Charles University, Vestec-Prague, Czechia. Electronic address: jiri.zahradnik2@gmail.com.
  • Ikeda T; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan. Electronic address: ikedat@kumamoto-u.ac.jp.
  • Takayama K; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan; AMED-CREST, Japan Agency for Medical Research and Development, Tokyo, Japan. Electronic address: kazuo.takayama@cira.kyoto-u.ac.jp.
  • Matsuno K; Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan; One Health Research Center, Hokkaido University, Sapporo, Japan; Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; International Col
  • Fukuhara T; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan; One Health Research Center, Hokkaido University, Sapporo, Japan; Graduate School of Medicine, Hokkaido Uni
  • Sato K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan; Interna
Cell Host Microbe ; 32(2): 170-180.e12, 2024 Feb 14.
Article em En | MEDLINE | ID: mdl-38280382
ABSTRACT
In late 2023, several SARS-CoV-2 XBB descendants, notably EG.5.1, were predominant worldwide. However, a distinct SARS-CoV-2 lineage, the BA.2.86 variant, also emerged. BA.2.86 is phylogenetically distinct from other Omicron sublineages, accumulating over 30 amino acid mutations in its spike protein. Here, we examined the virological characteristics of the BA.2.86 variant. Our epidemic dynamics modeling suggested that the relative reproduction number of BA.2.86 is significantly higher than that of EG.5.1. Additionally, four clinically available antivirals were effective against BA.2.86. Although the fusogenicity of BA.2.86 spike is similar to that of the parental BA.2 spike, the intrinsic pathogenicity of BA.2.86 in hamsters was significantly lower than that of BA.2. Since the growth kinetics of BA.2.86 are significantly lower than those of BA.2 both in vitro and in vivo, the attenuated pathogenicity of BA.2.86 is likely due to its decreased replication capacity. These findings uncover the features of BA.2.86, providing insights for control and treatment.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Idioma: En Ano de publicação: 2024 Tipo de documento: Article